This is a Phase Id, randomised, double-blind, placebo-controlled, multiple-dose, bridging study conducted at a single Phase I clinical research unit in Australia. The study is designed to evaluate the pharmacokinetics, safety, tolerability, and immunogenicity of XKH001 following repeated subcutaneous administration in healthy adult Caucasian participants, and to provide an ethnic-bridging pharmacokinetic comparison with the prior Phase I dataset in Chinese participants, required for XKH001's global development programme.
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Primary Outcome 1
Timeframe: Day 1, Day 29, and Day 57
Primary Outcome 2
Timeframe: Day 1, Day 29, and Day 57
Primary Outcome 3
Timeframe: Day 1, Day 29, and Day 57
Primary Outcome 4
Timeframe: Day 1, Day 29, and Day 57
Primary Outcome 5
Timeframe: Day 1, Day 29, and Day 57
Primary Outcome 6
Timeframe: Day 1, Day 29, and Day 57
Primary Outcome 7
Timeframe: Day 1, Day 29, and Day 57
Primary Outcome 8
Timeframe: Day 1, Day 29, and Day 57
Primary Outcome 9
Timeframe: Day 1, Day 29, and Day 57
Primary Outcome 10
Timeframe: Day 1, Day 29, and Day 57
Primary Outcome 11
Timeframe: Day 1, Day 29, and Day 57
Primary Outcome 12
Timeframe: Day 1, Day 29, and Day 57
Primary Outcome 13
Timeframe: Day 1, Day 29, and Day 57
Primary Outcome 14
Timeframe: Day 1, Day 29, and Day 57
Primary Outcome 15
Timeframe: first dose administration through Day 169
Primary Outcome 16
Timeframe: first dose administration through Day 169
Primary Outcome 17
Timeframe: first dose administration through Day 169
Primary Outcome 18
Timeframe: first dose administration through Day 169
Primary Outcome 19
Timeframe: first dose administration through Day 169